Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » 5 fold (Expand Search), _ fold (Expand Search)
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
mg decrease » _ decrease (Expand Search), nn decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
2 fold » 5 fold (Expand Search), _ fold (Expand Search)
-
61
-
62
-
63
-
64
-
65
-
66
Image_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.tif
Published 2021“…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …”
-
67
Predicted <i>cis</i>-acting elements in <i>DpAP2</i> promoter.
Published 2024“…Transgenic <i>D</i>. <i>parva</i> showed a higher carotenoid content (3.18 mg/g DW) compared with control group (2.13 mg/g DW) at 9 d. …”
-
68
-
69
-
70
-
71
-
72
-
73
-
74
DataSheet_1_Decrease in Serum Urate Level Is Associated With Loss of Visceral Fat in Male Gout Patients.docx
Published 2021“…</p>Results<p>ULT resulted in a mean (standard deviation) decrease in SU level (464.22 ± 110.21 μmol/L at baseline, 360.93 ± 91.66 μmol/L at the final visit, p <0.001) accompanied by a decrease in median (interquartile range) VFA [97.30 (81.15–118.55) at baseline, 90.90 (75.85–110.05) at the final visit, p < 0.001]. …”
-
75
-
76
-
77
-
78
-
79
-
80